Herpes Zoster Non-Live Recombinant Vaccine

BIOLOGICAL PAGE

Alberta Health Services
Communicable Disease Control

Section 7	Biological Product Information	**Standard # 07.215**	
Created and approved by	Provincial Immunization Program Standards and Quality		
Approval date	September 1, 2021	**Revised**	January 31, 2025

	SHINGRIX
Manufacturer	GlaxoSmithKline Inc.
Classification	Non-live recombinant, $AS01_B$ adjuvanted.

Indications for Provincially Funded Vaccine	• Solid Organ Transplant recipients 18 years of age and older (pre and post solid organ transplant).
	  ○ See Immunization of Adult Solid Organ Transplant Candidates and Recipients for additional information.
	• Autologous Hematopoietic Stem Cell Transplant (HSCT) recipients 18 years of age and older (post HSCT).
	  ○ See Immunization for Adult HSCT Transplant Recipients for additional information.

Serology	• Immunity screening after immunization is not recommended. ○ See Immunization of Adult Solid Organ Transplant Candidates and Recipients for additional information regarding serology recommendations.

Schedule	**Primary Series:**
	• Dose 1: Day 0
	• Dose 2: 2 to 6 months later.
	Note:
	• Do not immunize persons with active herpes zoster (HZ) with HZ vaccine.
	  ○ Vaccine may be considered at least 1 year after an episode of HZ disease.
	• SHINGRIX is recommended for those who have received live varicella vaccine prior to SOT transplant.
	  ○ SHINGRIX vaccine can be administered 8 weeks after live varicella vaccine.
	• SHINGRIX is recommended for those who have received Zostavax prior to solid organ transplant.
	  ○ An interval of 1 year is recommended between live attenuated Herpes Zoster (Zostavax) and SHINGRIX.

Preferred Use	N/A
Dose	0.5 mL
Route	IM
Contraindications/ Precautions	**Contraindications:** • Known severe hypersensitivity to any component of the vaccine. • Anaphylaxis to a previous dose of the vaccine. **Precautions:** • SHINGRIX is not indicated for prevention of primary varicella infection or for the treatment of HZ or postherpetic neuralgia (PHN).

	SHINGRIX
	• There are limited data available on the use of SHINGRIX in immunocompromised adults 50 years of age or older.
Possible Reactions	**Common:** • Pain, redness, itching and swelling at the injection site • Fever, chills • Fatigue, malaise • Headache, myalgia, arthralgia • Nausea, vomiting, diarrhea, abdominal pain. **Rare:** • Allergic reactions • Anaphylaxis • As with any immunization, unexpected or unusual side effects can occur. Refer to product monograph for more detailed information.
Pregnancy	Consult with the MOH. • There is no data on the use of SHINGRIX in pregnant individuals. • Not routinely recommended for pregnant individuals. • MOH will make an individual recommendation based on the risk of disease versus benefit of vaccine.
Lactation	Consult with the MOH. • There is no data on the use of SHINGRIX in lactating individuals. • Not routinely recommended for lactating individuals. • MOH will make an individual recommendation based on the risk of disease versus benefit of vaccine.
Composition	After reconstitution, one dose (0.5mL) contains: • 50 mcg Varicella Zoster Virus (VZV) glycoprotein E (gE) $AS01_B$Adjubant System (including suspension): • 50 mcg Quillaja saponaria Molina, fraction 21 (QS-21) • 50 mcg 3-O-desacyl-4'-monophosphoryl lipid A (MPL) • 1 mg dioleoyl phosphatidylcholine (DOPC) • 0.25 mg cholesterol • Disodium phosphate anhydrous • Potassium dihydrogen phosphate • Sodium chloride • Water for injection. Additional excipients - powder (gE): • dipotassium phosphate • polysorbate 80 • sodium dihydrogen phosphate dihydrate • sucrose.
Blood/Blood Products	Does not contain human blood/blood products.
Bovine/Porcine Products	Does not contain bovine or porcine products.
Latex	Does not contain latex.
Interchangeability	N/A

	SHINGRIX
Administration with Other Products	• SHINGRIX may be administered concomitantly with, or at any time before or after, other inactivated vaccines or live vaccines protecting against a different disease. • The vaccines should be administered at different injection sites.
Appearance	• The reconstituted vaccine is an opalescent, colourless to pale brownish liquid. • The lyophilized powder is white.
Storage	• Store both lyophilized vial and adjuvant solution at +2°C to +8°C. • Protect from light.
Preparation	• SHINGRIX must be reconstituted prior to administration. • Withdraw the entire contents of the vial containing the adjuvant suspension into a sterile syringe. • Add the entire contents of the syringe into the vial containing the lyophilized powder. • Shake gently until the lyophilized powder is completely dissolved. • Draw up entire content of the reconstituted vial.
Vaccine Code	Var-SI
Antigen Code	VZ
Licensed for	• Individuals 50 years of age and older. • Individuals 18 years of age and older who are or will be at increased risk of Herpes Zoster due to immunodeficiency or immunosuppression caused by known disease or therapy.
Program Notes	• 2017 October 13: Licensed for use in Canada. • 2021 September 1: Implemented for solid organ transplant recipients 18 years of age and older. • 2023 March 1: Updated to include reports of fever and shivering when co-administered with Pneumococcal 23-valent Polysaccharide (PPV23) Vaccine. • 2024 January 29: Expanded indications for provincially funded vaccine to include autologous HSCT recipients 18 years of age and older.
Related Resources	Herpes Zoster (Shingles) Vaccine – SHINGRIX (VAR-SI) Information Sheet

References

Alberta Health. (2024, January 29). Herpes Zoster Non-Live Recombinant Vaccine (Shingrix). In *Alberta Immunization Policy: Biological Products.* Government of Alberta.

Alberta HSCT program physicians. Expert opinion. November 2023. In *Alberta Immunization Policy: Herpes Zoster Non-Live Recombinant Vaccine (Shingrix).* Government of Alberta.

Alberta Infectious Disease and Solid Organ Transplant program physicians. Expert opinion. November 2019. In *Alberta Immunization Policy: Herpes Zoster Non-Live Recombinant Vaccine (Shingrix).* Government of Alberta.

GlaxoSmithKline (2022, November 15). SHINGRIX: Herpes Zoster vaccine (non-live recombinant, $AS01_B$ adjuvanted). Health Canada Drug Product Database. https://pdf.hres.ca/dpd_pm/00068227.PDF

Immunize .org. (2022, March 9). Ask the Experts: Zoster (Shingles). National Advisory Committee on Immunization. (2018, August 30). *Updated Recommendations on the Use of Herpes Zoster Vaccines: An advisory committee statement.* Public Health Agency of Canada.

Public Health Agency of Canada. (2023, October). Herpes zoster (shingles) vaccine. In *Canadian Immunization Guide*. Government of Canada.